Skip to main content

CNTX

Stock
Health Care
Biotechnology

Performance overview

CNTX Price
Price Chart

Forward-looking statistics

Beta
0.52
Risk
84.49%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

context therapeutics is dedicated to discovering, acquiring, and developing novel compounds to treat hormone responsive cancers. our lead program is apristor (onapristone xr), an investigational drug for progesterone receptor positive (pr+) breast cancer. up to 70% of breast cancers express progesterone receptor (pr). if your cancer is pr+, apristor could be an option for you.

Company info

SectorHealth Care
IndustryBiotechnology
Employees7
Market cap$128.2M

Fundamentals

Enterprise value-$30.4M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity0.21

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.28
Dividend per share—
Revenue per share$0.00
Avg trading volume (30 day)$224K
Avg trading volume (10 day)$112K
Put-call ratio—

Macro factor sensitivity

Growth+7.3
Credit-2.5
Liquidity-6.9
Inflation+7.6
Commodities+1.5
Interest Rates-3.4

Valuation

Dividend yield0.00%
PEG Ratio-2.21
Price to sales—
P/E Ratio-2.21
Enterprise Value to Revenue—
Price to book0.63

Upcoming events

Next earnings dayMay 9, 2024
Next dividend day—
Ex. dividend day—

News

Bet on These 5 Top-Ranked Stocks With Rising P/E

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Carvana, Context Therapeutics Inc, Inovio Pharmaceuticals, ChargePoint and MSA Safety Inc.

Zacks Investment Research (April 21, 2025)
Context Therapeutics Shares Surge On Encouraging Data From Onapristone In Early Breast Cancer

Context Therapeutics IncĀ (NASDAQ: CNTX) postedĀ data from the window-of-opportunity trialĀ of onapristone extended-release (ONA-XR) in postmenopausal patients with progesterone receptor-positive (PR+) early breast cancer.Ā The data were presented at San Antonio Breast Cancer Symposium.

Benzinga (December 10, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free